Prothena Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 08/08/24
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/25/24
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationBusiness Wire • 05/28/24
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D ExpensesZacks Investment Research • 05/09/24
Prothena Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 05/08/24
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to DeclineZacks Investment Research • 04/25/24
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaBusiness Wire • 04/15/24
Prothena Announces Appointment of Daniel G. Welch as Director and Chair DesignateBusiness Wire • 02/21/24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness Wire • 02/15/24
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024Business Wire • 02/08/24